kabutan

RaQualia Pharma Inc.(4579) Summary

4579
TSE Growth
RaQualia Pharma Inc.
1,212
JPY
-90
(-6.91%)
Dec 12, 3:30 pm JST
7.77
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
1,310
Dec 13, 1:28 am JST
Summary Chart Historical News Financial Result
PER
PBR
4.94
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
1,278 JPY 8.21 USD
Previous Close Dec 11
1,302 JPY 8.34 USD
High Dec 12, 9:03 am
1,296 JPY 8.33 USD
Low Dec 12, 1:27 pm
1,176 JPY 7.55 USD
Volume
1,202,300
Trading Value
1.47B JPY 9.41M USD
VWAP
1220.05 JPY 7.83 USD
Minimum Trading Value
121,200 JPY 777 USD
Market Cap
0.03T JPY 0.19B USD
Number of Trades
3,586
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
High
1-Year Average
1,005
1-Year High Dec 2, 2025
41,024
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 2,200 2,848,700 1294.86
Nov 28, 2025 44,300 2,360,500 53.28
Nov 21, 2025 1,900 2,083,500 1096.58
Nov 14, 2025 1,000 1,723,400 1723.40
Nov 7, 2025 0 1,737,400
Company Profile
RaQualia Pharma Inc. is a drug discovery venture company specializing in pain disorders. Its main revenue source is the out-licensing of intellectual property rights for drug candidates.
Sector
Pharmaceuticals
RaQualia Pharma Inc. is a research and development-oriented drug discovery venture with a business model focused on out-licensing intellectual property rights of novel drug candidates to pharmaceutical companies. The company conducts drug discovery research and development for high-need medical conditions, primarily in gastrointestinal and pain disorders. RaQualia Pharma Inc. pursues agile and flexible business activities, offering its entire research and development portfolio for out-licensing at various stages, from early exploration to clinical development. The company actively engages in open innovation-based research and development, addressing a wide range of disease areas through industry-academic collaborations. RaQualia Pharma Inc. has built a research and development portfolio comprising multiple projects, including out-licensing preparation programs, out-licensed programs, and collaborative research programs.